

FORMATO EUROPEO
PER IL CURRICULUM
VITAE



INFORMAZIONI PERSONALI

Nome	Dott. Eugenio Villa
Indirizzo	
Telefono	02.2643.7620
Fax	02.2643.7640
E-mail	villa.eugenio@hsr.it
Nazionalità	Italiana
Data di nascita	Ornago (MI) il 14 Marzo 1948

ESPERIENZA LAVORATIVA

- | | | |
|-----------------|-------------------|--|
| • Date (da – a) | 2004 | Primario U.O. Oncologia Medica IRCCS H. San Raffaele - Milano |
| | 1993 | Primario del U.O. di Radiochemioterapia (Oncologia Medica e Radioterapia) IRCCS Ospedale San Raffaele – Milano |
| | 1983 | Specializzazione in Radiologia e Radioterapia presso l'Università degli Studi di Milano |
| | 1982 | Aiuto IRCCS Ospedale San Raffaele |
| | 1979-1982 | Assistente IRCCS Ospedale San Raffaele |
| | 1978 | Specializzazione in Oncologia presso l'Università di Modena |
| | 1975-1979 | Specializzando in Istituto Nazionale dei Tumori |
| | 10/10/1975 | Laurea in Medicina e Chirurgia |
-
- | | |
|---|---|
| • Nome e indirizzo del datore di lavoro | Fondazione Centro San Raffaele del Monte Tabor |
| • Tipo di azienda o settore | Istituto di Ricovero e cura a carattere scientifico |
| • Tipo di impiego | <i>Primario U.O. Oncologia Medica</i> |
| • Principali mansioni e responsabilità | |

Iscrizione ad organizzazioni

Associazione Italiana Medici Oncologi AIOM

professionali: Associazione Italiana Radioterapia Oncologica AIRO
European Society of Medical Oncology ESMO
European Society of Therapeutic Radiology and Oncology ESTRO
American Society of Clinical Oncology ASCO
American Society for Therapeutic Radiology and Oncology ASTRO

Attività Didattica:

1999 Docente di Oncologia come Professore a Contratto presso il Corso di Laurea in Medicina e Chirurgia dell'Università Vita - Salute San Raffaele.
Docente di Oncologia presso il Corso di Laurea Infermieristica Università Vita Salute Ospedale San Raffaele
Docente di Oncologia come Professore a Contratto delle Scuole di Specializzazione in Chirurgia, Urologia, Gastroenterologia dell'Università Vita-Salute San Raffaele.

1997 Docente di Oncologia come Professore a Contratto del Corso di Laurea presso l'Università degli Studi di Milano Corso Integrato di Tecniche Infermieristiche applicate alla Medicina Clinica Specialistica – Disciplina Oncologia Medica.

1993 Docente di Oncologia e Radioterapia come Professore a Contratto del Corso Integrato di Oncologia Clinica – Didattica non formale (in associazione con il Prof. C. Besana e il Prof. F. Milani) presso l'Università degli Studi di Milano.

1990 Professore a Contratto presso le Scuole di Specializzazione in Endocrinologia, Radioterapia, Chirurgia d'Urgenza presso l'Università degli Studi di Milano.

Principali Pubblicazioni:

Ferreri AJM, Reni M, Bolognesi A, Verusio C, Villa E
Combined therapy for primary central nervous system lymphoma in immunocompetent patients
Eur J Cancer 1995; 31A (12): 2008-2012

Ferreri AJM, Reni M, Zoldan MC, Terreni MR, Villa E
Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion
Cancer 1996; 77 (5): 827-833

Reni M, Ferreri AJM, Garancini MP, Villa E
Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature
Ann Oncol 1997; 8: 1-8

Ceresoli GL, Ferreri AJM, Bucci E, Ripa C, Ponzoni M, Villa E
Primary cardiac lymphoma in immunocompetent patients: diagnostic and therapeutic management
Cancer 1997; 80: 1497-1506

Ferreri AJM, Ponzoni M, Cordio S, Vanzulli A, Garuti E, Viale E, Villa E
Low sensitivity of computed tomography in the staging of gastric lymphomas of mucosa-associated lymphoid tissue
Am J Clin Oncol 1998; 21 (6): 614-616

Reni M, Ferreri AJM, Villa E
Second-line treatment for primary central nervous system lymphoma
British Journal of Cancer 1999; 79 (3/4): 530-534

Ferreri AJM, Reni M, Villa E
Therapeutic management of primary central nervous system lymphoma:
lessons from prospective trials
Ann Oncol 2000; 11 (8): 927-937

Ceresoli GL, Dell'Oro S, Passoni P, Villa E
Phase II study of paclitaxel and epirubicin as first-line treatment in
patients with metastatic non-small cell lung carcinoma
Cancer 2000; 89 (1): 89-96

Reni M, Ferreri AJM, Landoni C, Villa E
Salvage therapy with temozolomide in an immunocompetent patient
with primary brain lymphoma
J Natl Cancer Inst. 2000; 92 (7): 575-6

Favaretto A, Ceresoli GL, Paccagnella A, Barbieri F, Bearz A, Ghiotto
C, Oniga F, Schiavon S, Frustaci S, Villa E for the Gruppo Studio
Tumori Polmonari Veneto (GSTPV)
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II
trial in patients with advanced non-small-cell lung cancer
Ann Oncol 2000; 11; 1421-1426

Reni M, Panucci MG, Ferreri AJM, Balzano G, Passoni P, Cattaneo
GM, Cordio S, Scaglietti U, Zerbi A, Ceresoli GL, Fiorino C,
Calandrino R, Staudacher C, Villa E, Di Carlo V
Effect on local control and survival of electron beam intraoperative
irradiation for resectable pancreatic adenocarcinoma
International Journal of Radiation Oncology, Biology and Physics 2001;
50 (3): 651-658

Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, Zerbi
A, Di Carlo V, Villa E
Definitive results of a phase II trial of Cisplatin, Epirubicin, continuous-
infusion Fluorouracil, and gemcitabine in stage IV pancreatic
adenocarcinoma
Journal of Clinical Oncology 2001; 19: 2679-2686

Reni M, Panucci MG, Balzano G, Ferreri AJM, Passoni P, Zerbi A,
Cordio S, Ceresoli GL, Dell'Oro S, Staudacher C, Di Carlo V, Villa E
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a
comparison among three regimens
III Congresso Nazionale AIOM – Napoli, 4-7 novembre 2001 (poster
discussion)
Annals of Oncology 2001; 12 (Suppl. 4): L34

Ferreri AJM, Ponzoni M, Pruneri G, Freschi M, Rossi R, Dell'Oro S,
Baldini L, Buffa R, Carboni N, Villa E, Viale G

Immunoreactivity for p27^{KIP1} and cyclin e is Antiemetic independent predictor of survival in primary gastric non-Hodgkin's lymphoma
International Journal of Cancer 2001; 94: 599-604

Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Romeo D, Caroti C, Farris A, Cruciani G, Villa E, Schieppati G, Mustacchi G; Italian Breast Cancer Cooperative Group.

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.

J Clin Oncol 2001 Nov 15;19(22):4209-15

Della Volpe A, Ferreri AJ, Annaloro C, Mangili P, Rosso A, Calandrino R, Villa E, Lambertenghi-Delilieri G, Fiorino C.

Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation.

Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):483-8

Ceresoli GL, Reni M, Chiesa G, Carretta A, Schipani S, Passoni P, Bolognesi A, Zannini P, Villa E

Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.

Cancer 2002 Aug 1;95(3):605-12

Cozzarini C, Fiorino C, Ceresoli GL, Cattaneo G, Bolognesi A, Calandrino R, Villa E

Significant correlation between rectal dhv and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6 - 70.2 Gy)

Int J Rad Oncol Biol Phys 2003; 55 (3): 688-694

Ponzoni M, Ferreri AJM, Pruneri G, Pozzi B, Dell'Oro S, Pigni A, Pinotti G, Villa E, Freschi M, Viale G, Capella C

Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome

International Journal of Cancer 2003; 106: 288-291

Cappuzzo F, Bartolini S, Ceresoli GL, Tamperi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crinò L

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer

British Journal of Cancer 2004; 90 (1): 82 - 86

Ferreri AJM, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubnik A, Calderoni A, Spina M; Brandes A, Ferrarese F, Rognone A, Govi S, Dell'Oro S, Locatelli M, Villa E, Reni M

Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas

British Journal of Cancer 2004; 90 (2): 353 - 358

Reni M, Brandes AA, Vavassori V, Cavallo G, Casagrande F, Vastola F, Magli A, Franzin A, Basso U, Villa E

A multicenter study of the prognosis and treatment of adult brain ependymal tumors

Cancer 2004; 100 (6): 1221 – 1229

Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli V, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V

Cisplatin versus carboplatin in combination with mitomycin and vinblastin in advanced non small cell lung cancer. A multicenter, randomized phase III trial

Lung Cancer 2004; 43 (1): 83 – 91

Ferreri AJM, Guidoboni M, Ponzoni M, De Conciliis C, Dell'Oro S, Fleischhauer K, Caggiari L, Lettini AA, Dal Cin E, Ieri R, Freschi M, Villa E, Boiocchi M, Dolcetti R

Evidence for an association between chlamydia psittaci and ocular adnexal lymphomas

Journal of National Cancer Institute 2004; 96 (8): 586 – 594

Ceresoli GL, Gregorc V, Cordio S, Bencardino KB, Schipani S, Cozzarini C, Bordonaro R, Villa E

Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer

Lung Cancer 2004, 44: 231-239

Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E
Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial

Annals of Oncology 2004; 15 (7): 1042-1047

Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJM

Salvage therapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial

European Journal of Cancer 2004; 40 (11): 1682-1688

Venturini M, Angeli E, Salvioni M, De Cobelli F, Ronzoni M, Aldrighetti L, Stella M, Carlucci M, Staudacher C, Di Carlo V, Ferla G, Villa E, Del Maschio A

Complication after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical relevance and management in 204 patients

AJR Am J Roentgenol 2004; 182 (6): 1417 – 1426

Reni M, Panucci MG, Passoni P, Bonetto E, Nicoletti R, Ronzoni M, Zerbi A, Staudacher C, Di Carlo V, Villa E

Salvage chemotherapy with Mitomycin, Docetaxel and Irinotecan (MDI

regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial
Cancer Investigation 2004; 22 (5): 688 – 696

Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani CI Luppi G,
Nicoletti R, Galli L. Bordonaro R, Passardi A, Zerbi A, Balzano G,
Aldrighetti L, Staudacher C, Villa E, Di Carlo V
Gemcitabine versus cisplatin, epirubicin, fluorouracil and gemcitabine in
advanced pancreatic cancer: a randomised controlled multicentre phase
III trial
Lancet Oncology 2005; 6: 369 – 376

Reni M, Passoni P, Bonetto E, Balzano G, Panucci MG, Zerbi A,
Ronzoni M, Staudacher C, Villa E, Di Carlo V
Final results of a prospective trial of PEFG (Cisplatin, Epirubicin, 5-
Fluorouracil, Gemcitabine) regimen followed by radiotherapy after
curative surgery for pancreatic adenocarcinoma
Oncology 2005; 68: 239 – 245

Ferreri AJM, Ponzoni M, Guidoboni M, De Conciliis C, Resti AG,
Mazzi B, Lettini AA, Demeter J, Dell'Oro S, Doglioni C, Villa E,
Boiocchi M, Dolcetti R
Regression of ocular adnexal lymphoma after Chlamydia Psittaci-
eradicating antibiotic therapy
J Clin Oncol 2005 Aug 1; 23 (22): 5067 – 5073

Cusatis, G; Gregorc, V; Li, J; Spreafico, A; Ingersoll, RG; Verweij, J;
Ludovini, V; Villa, E; Hidalgo, M; Sparreboom, A; Baker, SD. J. Natl.
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Cancer Inst.: 2006; 98(23): 1739-1742 - Article. Impact Factor 2006:
15,271

Pulitano, C; Aldrighetti, L; Arru, M; Vitali, G; Ronzoni, M; Catena, M;
Finazzi,R;Villa,E;Ferla,G.
Influence of preoperative chemotherapy on the risk of major
hepatectomy for colorectal liver metastases.
Ann. Surg.: 2006; 244(5): 833-835 - Letter. Impact Factor 2006: 7,678

Ceresoli, GL; Cattaneo, GM; Castellone, P; Rizzo, G; Landoni, C;
Gregorc, V; Calandrino, R; Villa, E; Messa, C; Santoro, A; Fazio, F.
Role of computed tomography and [18F] fluorodeoxyglucose positron
emission tomography image fusion in conformal radiotherapy of non-
small cell lung cancer: a comparison with standard techniques with and
without elective nodal irradiation. Tumori: 2007; 93(1): 88 - 96 -
Article. Impact Factor 2007: 0,597

Giovannini, M; Gregorc, V; Vigano, MG; Spreafico, A; Ghio, D;
Dell'Oca, I; Bolognesi, A; Villa, E. Endothelial
growth factor receptor inhibition after radiotherapy. J. Thorac. Oncol.:
2007; 2(7): 662- - Article. Impact Factor 2007: 1,429

Gregorc, V; Spreafico, A; Floriani, I; Colombo, B; Ludovini, V; Pistola,
L; Bellezza, G; Vigano, MG; Villa, E; Corti, A.

Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. *Cancer*: 2007; 110(4): 845-853 - Article. Impact Factor 2007: 4,632

Giovannini, M; Belli, C; Villa, E; Gregorc, V. Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? *J. Thorac. Oncol.*: 2008; 3(6): 684-685 - Letter. Impact Factor 2008: 3,508

Gregorc, V; Hidalgo, M; Spreatico, A; Cusatis, G; Ludovini, V; Ingersoll, RG; Marsh, S; Steinberg, SM; Vigano, MG; Ghio, D; Villa, E; Sparreboom, A; Baker, SD. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. *Clin. Pharmacol. Ther.*: 2008; 83(3): 477-484 - Article. Impact Factor 2008: 7,586

Pulitano, C; Arru, M; Catena, M; Guzzetti, E; Vitali, G; Ronzoni, M; Venturini, M; Villa, E; Ferla, G; Aldrighetti, L. Results of preoperative hepatic arterial infusion chemotherapy in patients undergoing liver resection for colorectal liver metastases. *Ann. Surg. Oncol.*: 2008; 15(6): 1661-1669 - Article. Impact Factor 2008: 3,898

Giovannini, M; Gregorc, V; Belli, C; Roca, E; Lazzari, C; Vigano, MG; Serafico, A; Villa, E. Clinical significance of skin toxicity due to EGFR-targeted Therapies. *J. Oncol.*: 2009; 849051- Review.

Reni, M; Cereda, S; Balzano, G; Passoni, P; Rognone, A; Fugazza, C; Mazza, E; Zerbi, A; Di Carlo, V; Villa, E. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. *Cancer*: 2009; 115(12): 2630-2639 - Article. Impact Factor 2008: 5,238

Reni, M; Cereda, S; Balzano, G; Passoni, P; Rognone, A; Zerbi, A; Nicoletti, R; Mazza, E; Arcidiacono, PG; Di Carlo, V; Villa, E. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. *Cancer Chemother. Pharmacol.*: 2009; 64(6): 1253-1259 - Article. Impact Factor 2008: 2,740

Cereda S, Rognone A, Mazza E, Fugazza C, Ceraulo D, Villa E, Reni M. Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer. *M. J. Chemother.* 2009 Dec;21(6):698-700. Impact Factor 2008: 0,843

Cereda S, Passoni P, Reni M, Viganò MG, Aldrighetti L, Nicoletti R, Villa E. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. *Cancer*. 2010

Matteo G. Carrabba MD, Michele Reni MD, Marco Foppoli MD, Anna Chiara MD, Alberto Franzin MD, Letterio Salvatore Politi MD, Eugenio Villa MD, Fabio Ciceri MD, and Andrés J. M. Ferreri MD. Treatment approaches for primary CNS lymphomas. Expert Opinion in Pharmacotherapy. Impact Factor 2008: 2,077

Reni M¹, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E.
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23. doi: 10.1007/s00280-011-1680-2. Epub 2011 May 28.

Cereda S¹, Reni M, Rognone A, Fugazza C, Ghidini M, Ceraulo D, Brioschi M, Nicoletti R, Villa E
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy. 2011;57(2):156-61. doi: 10.1159/000324865. Epub 2011 Mar 31.

Ferreri AJ, Verona C, Politi LS, Chiara A, Perna L, Villa E, Reni M. Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):169-75. doi: 10.1016/j.ijrobp.2010.01.066. Epub 2010 Jun 26

Manzoni M¹, Mariucci S, Delfanti S, Rovati B, Ronzoni M, Loupakis F, Brugnatelli S, Tinelli C, Villa E, Falcone A, Danova M
Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol. 2012 Jul;138(7):1187-96. doi: 10.1007/s00432-012-1190-6. Epub 2012 Mar 15.

Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Di Muzio N, Di Carlo V, Villa E.
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol. 2012 Jul;19(7):2256-63. doi: 10.1245/s10434-011-2205-2. Epub 2012 Jan 12.

Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E.


A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).

Cancer Chemother Pharmacol. 2012 Jan;69(1):115-23. doi: 10.1007/s00280-011-1680-2. Epub 2011 May 28

Reni M, Cereda S, Milella M, Novarino A, Passardi A, Mambrini A, Di Lucca G, Aprile G, Belli C, Danova M, Bergamo F, Franceschi E, Fugazza C, Ceraulo D, Villa E

Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial.

Eur J Cancer. 2013 Nov;49(17):3609-15. doi: 10.1016/j.ejca.2013.06.041. Epub 2013 Jul 27.


Dr. Eugenio Villa

Milano, 18/12/2014